A detailed history of Black Rock Inc. transactions in 89bio, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 7,015,575 shares of ETNB stock, worth $61.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,015,575
Previous 6,637,984 5.69%
Holding current value
$61.9 Million
Previous $77.3 Million 27.27%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$7.31 - $10.9 $2.76 Million - $4.12 Million
377,591 Added 5.69%
7,015,575 $56.2 Million
Q1 2024

May 10, 2024

BUY
$8.13 - $13.77 $9.62 Million - $16.3 Million
1,183,788 Added 21.7%
6,637,984 $77.3 Million
Q4 2023

Feb 13, 2024

BUY
$6.66 - $16.03 $3.25 Million - $7.82 Million
487,956 Added 9.83%
5,454,196 $60.9 Million
Q3 2023

Nov 13, 2023

BUY
$15.06 - $19.41 $4.76 Million - $6.13 Million
316,057 Added 6.8%
4,966,240 $76.7 Million
Q2 2023

Aug 11, 2023

BUY
$14.15 - $22.03 $48.1 Million - $74.9 Million
3,400,611 Added 272.14%
4,650,183 $88.1 Million
Q1 2023

May 12, 2023

BUY
$10.48 - $16.94 $1.89 Million - $3.05 Million
179,991 Added 16.83%
1,249,572 $19 Million
Q4 2022

Feb 13, 2023

BUY
$5.52 - $12.73 $880,655 - $2.03 Million
159,539 Added 17.53%
1,069,581 $13.6 Million
Q3 2022

Nov 14, 2022

BUY
$3.02 - $7.0 $1.16 Million - $2.68 Million
382,677 Added 72.56%
910,042 $5.27 Million
Q2 2022

Aug 12, 2022

SELL
$2.09 - $4.02 $825,267 - $1.59 Million
-394,865 Reduced 42.82%
527,365 $1.7 Million
Q1 2022

May 12, 2022

BUY
$3.45 - $14.99 $243,187 - $1.06 Million
70,489 Added 8.28%
922,230 $3.48 Million
Q4 2021

Feb 10, 2022

BUY
$11.15 - $19.66 $1.33 Million - $2.35 Million
119,347 Added 16.3%
851,741 $11.1 Million
Q3 2021

Nov 09, 2021

SELL
$14.91 - $21.31 $107,486 - $153,623
-7,209 Reduced 0.97%
732,394 $14.3 Million
Q2 2021

Aug 11, 2021

BUY
$17.42 - $28.0 $12.9 Million - $20.7 Million
739,603 New
739,603 $13.8 Million

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $410M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.